Bionano Genomics (BNGO) Accounts Payables (2017 - 2026)

Bionano Genomics' Accounts Payables history runs 10 years deep, the most recent figure standing at $5.1 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 22.86% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $5.1 million (down 22.86% YoY), while the FY2025 annual figure was $5.6 million, down 19.71% from the prior year.
• Accounts Payables came in at $5.1 million for Q1 2026 at Bionano Genomics, down from $5.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $15.8 million in Q1 2023 to a low of $5.1 million in Q1 2026.
• A 5-year average of $9.0 million and a median of $8.7 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables jumped 198.33% in 2022 and sank 43.39% in 2024, its largest moves.
• Bionano Genomics' Accounts Payables stood at $12.5 million in 2022, then fell by 17.15% to $10.4 million in 2023, then sank by 32.95% to $7.0 million in 2024, then dropped by 19.71% to $5.6 million in 2025, then slipped by 9.45% to $5.1 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $5.1 million, $5.6 million, and $6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison